The component analysis reflected that among antiplatelets the use of ASA, cilostazol, dipyridamole, and the P2Y12 blocker clopidogrel, ticlopidine, and ticagrelor conveyed a significant reduction of stroke risk. Here, P2RY12 is linked to Stroke.